TheStreet upgraded shares of BioNTech (NASDAQ:BNTX) from a c rating to a b- rating in a report published on Monday, TheStreetRatingsTable reports.
Several other analysts have also recently weighed in on BNTX. Jefferies Financial Group set a $230.00 price target on BioNTech in a report on Thursday, October 7th. Berenberg Bank set a $400.00 price target on BioNTech in a report on Tuesday, October 5th. Zacks Investment Research raised BioNTech from a hold rating to a buy rating and set a $272.00 target price on the stock in a research report on Tuesday. Redburn Partners reaffirmed a sell rating and set a $146.00 target price on shares of BioNTech in a research report on Wednesday, June 16th. They noted that the move was a valuation call. Finally, UBS Group set a $300.00 target price on BioNTech in a research report on Thursday, September 23rd. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating and five have issued a buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of Hold and an average target price of $255.36.
Shares of BNTX stock opened at $249.40 on Monday. The company has a debt-to-equity ratio of 0.04, a quick ratio of 2.57 and a current ratio of 2.67. The company has a market capitalization of $60.48 billion, a P/E ratio of 13.05 and a beta of -1.59. The company’s 50 day moving average price is $331.44 and its two-hundred day moving average price is $249.12. BioNTech has a 52 week low of $75.35 and a 52 week high of $464.00.
Several hedge funds have recently bought and sold shares of the company. Primecap Management Co. CA grew its stake in shares of BioNTech by 4.2% during the 1st quarter. Primecap Management Co. CA now owns 4,821,718 shares of the company’s stock worth $526,483,000 after acquiring an additional 193,521 shares during the period. Price T Rowe Associates Inc. MD grew its stake in shares of BioNTech by 31.8% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 2,074,906 shares of the company’s stock worth $226,559,000 after acquiring an additional 500,085 shares during the period. FMR LLC grew its stake in shares of BioNTech by 13.8% during the 2nd quarter. FMR LLC now owns 1,997,013 shares of the company’s stock worth $447,092,000 after acquiring an additional 242,867 shares during the period. Fosun International Ltd bought a new position in shares of BioNTech during the 2nd quarter worth $353,904,000. Finally, BlackRock Inc. grew its stake in shares of BioNTech by 99.4% during the 2nd quarter. BlackRock Inc. now owns 1,481,390 shares of the company’s stock worth $331,654,000 after acquiring an additional 738,532 shares during the period. Institutional investors own 14.49% of the company’s stock.
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is involved in the developing of FixVac product candidates, including BNT111, which is in Phase I clinical trial for advance melanoma; BNT112 that is in Phase I/IIa trial for prostate cancer; BNT113, which is in Phase I/II trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115 in a Phase I trial in ovarian cancer; and BNT116 for non-small cell lung cancer.It also develops neoantigen specific immunotherapies, such as Autogene cevumeran (BNT122), which is in Phase II clinical trial for first-line melanoma, as well as in Phase I clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 to treat multiple solid tumors.
Receive News & Ratings for BioNTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioNTech and related companies with MarketBeat.com's FREE daily email newsletter.